Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 227

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 8
Chunk 227
---
QUITY SECURITIES AND USE OF PROCEEDS

Purchases of Equity Securities by the Registrant

The following table provides information on our share repurchases during the quarter ended June 30, 2025:

Issuer Purchases of Equity SecuritiesPeriodTotal Numberof Shares PurchasedAverage PricePaid Per Share (1)Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs (2)Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs (1)April 1, 2025 – April 30, 2025—$— —$300,000,000 May 1, 2025 – May 31, 20251,955,589$25.59 1,955,589$249,999,997 June 1, 2025 –June 30, 2025—$— —$249,999,997 Total1,955,589$25.59 1,955,589$249,999,997 

(1) The average price paid per shares excludes less than $0.1 million of broker fees and $0.4 million of excise tax incurred on share repurchases for the three months ended June 30, 2025. The remaining authorization outstanding for repurchases of common stock also excludes broker fees and the excise tax incurred.

(2) Our Board of Directors has authorized the repurchase of common stock under a share repurchase program adopted and announced in April 2025. The share repurchase program authorizes the Company to purchase up to an aggregate of $300.0 million of the Company’s outstanding common stock. Repurchases under this program may be made at management’s discretion on the open market or through privately negotiated transactions, including plans that comply with Rule 10b5-1 under the Exchange Act. The share repurchase program may be suspended or discontinued at any time by the Company and has an expiration date of December 31, 2026.

The timing of any repurchases and the actual number of shares repurchased will depend on a variety of factors, including our stock price, corporate and regulatory requirements, tax implications, restrictions under our debt obligations, other uses for capital, impacts on the value of remaining shares, and market and economic conditions.

Refer to Note 11, Stockholders’ Equity, to our condensed consolidated financial statements included herein for more information on our share repurchases.

Item 3. DEFAULTS UP